Revive Therapeutics Announces Finalization of Amended Phase 3 COVID-19 Study Protocol to FDA

by rvvadmin | Oct 14, 2022 | 2022

TORONTO, Oct. 14, 2022- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

by rvvadmin | Oct 6, 2022 | 2022

TORONTO, Oct. 06, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19

by rvvadmin | Sep 28, 2022 | 2022

TORONTO, Sept. 28, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, today...

Revive Therapeutics Provides Update on the Psilocybin Clinical Study for Methamphetamine Use Disorder and Oral Psilocybin Thin Film Strip Program

by rvvadmin | Sep 16, 2022 | 2022

TORONTO, Sept. 16, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased...

Revive Therapeutics Announces Submission of Amended Phase 3 COVID-19 Study Protocol to FDA

by rvvadmin | Sep 14, 2022 | 2022

TORONTO, Sept. 14, 2022 – Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced...